Google Ads and GLP-1 Offers: Certification, Restricted Terms, and Ban Triggers

Can you run Google Ads for semaglutide or tirzepatide offers?

Yes, within two separate lanes. Google's restricted drug terms policy lets any advertiser targeting the US, Canada or New Zealand use prescription drug terms in ad text and landing pages without certification — but keyword-targeting those same terms is a different matter entirely. Google states plainly that "you must be certified in order to keyword-target these terms," which means bidding on "tirzepatide" or "Ozempic" as a search term requires certification most supplement and info-product sellers cannot obtain.

Certification runs through two gatekeepers. Online pharmacies need LegitScript Healthcare Merchant Certification or NABP accreditation; telemedicine providers need LegitScript certification specifically. Either way, Google adds a second layer on top — the advertiser must also hold Google's own certification before the account can bid on restricted terms. Working through LegitScript certification for GLP-1 telehealth before you touch keyword strategy saves months of wasted spend chasing a certification you don't yet have.

Google's prescription drug reference list is not exhaustive, but it does name names: semaglutide, tirzepatide, liraglutide, Ozempic, Wegovy, Mounjaro and Zepbound all appear on it explicitly. That list matters for classification. A product sharing a molecule name with an approved drug gets treated as a prescription drug term regardless of who is selling it, compounded pharmacy or brand manufacturer alike.

What certifications does Google require for prescription drug advertisers?

Google requires two certifications stacked on top of each other, not one. The first proves the business is legitimate — LegitScript Healthcare Merchant Certification or NABP accreditation for a pharmacy, LegitScript certification alone for a telemedicine provider. The second is Google's own advertiser certification, granted only after the first is in hand, and it's the second one that actually authorizes keyword-targeting of restricted drug terms.

Meta and TikTok run parallel but not identical gauntlets, and the differences change which platform fits a given business model:

Which drug terms are restricted in ad copy and landing pages?

Restricted drug terms cover the molecule and brand names of prescription drugs. The list Google publishes names semaglutide, tirzepatide, liraglutide, Ozempic, Wegovy, Mounjaro and Zepbound outright, and Google treats it as non-exhaustive. In the US, Canada and New Zealand you can print those words in ad copy and on your landing page without certification. You cannot buy the keyword.

A separate layer of Google's healthcare and medicines policy bans specific ingredient categories outright, independent of certification status:

• Products containing ephedra
• Products containing human chorionic gonadotropin (hCG) in relation to weight loss or weight control
• Herbal and dietary supplements containing active pharmaceutical or dangerous ingredients

Can weight-loss supplements bid on Ozempic and GLP-1 keywords?

Not safely, and not for long. Bidding on the keyword itself requires certification a supplement or research-peptide seller structurally cannot obtain, since Google reserves that certification for online pharmacies, telemedicine providers and pharmaceutical manufacturers. Try anyway and keyword-targeting enforcement catches the ad before the creative even gets scrutinized.

Even reference-only copy runs into a second wall. Google's unapproved substances policy bans, "regardless of any claims of legality," products that "imply they are as effective as prescription drugs" — the exact trap a "natural Ozempic" or "GLP-1 alternative" headline sets for itself. Before writing that headline, pull the field through the Google Ads Transparency Center and see what language actually survived review versus what got pulled.

The FDA layer compounds the risk rather than replacing it. Under 21 CFR 101.93(g)(2), naming a prescription drug in supplement labeling is itself evidence of an implied disease claim, and section (g)(2)(iv)(B) specifically flags an ingredient "well known to consumers for its use or claimed use in preventing or treating a disease" — precisely what "for Ozempic users" or "eases GLP-1 side effects" positioning does. Testing angles with AI UGC ad tools for supplement offers doesn't fix this; the claim itself is the liability, not the production value behind it.

What happens to non-certified advertisers who mention drug names?

Reference without keyword-targeting stays a routine policy matter, not a death sentence for the account. Mention "tirzepatide" in body copy without bidding on it as a keyword, and the enforcement, if any, is disapproval of the individual ad or restriction of keyword eligibility — not automatic account suspension, contrary to what a lot of agency scare copy implies.

Where accounts actually die is evasion, not mention. Google's Abusing the ad network policy treats "circumventing systems" and "evasive ad content" as an egregious violation, defining the latter as manipulation of ad components such as text, images, domains or subdomains to bypass detection. Google states "your Google Ads accounts will be suspended upon detection and without prior warning, and you will not be allowed to advertise with Google Ads again." Rotating domains to dodge a drug-term disapproval is exactly the pattern that policy exists to catch.

Checking whether a disapproval is about to escalate starts with checking what's actually live. Pull the account's pattern against what similar advertisers are running via how to see competitors' Google Ads before assuming a single disapproved ad means the account sits on a suspension countdown.

How long does healthcare certification take and what does it cover?

Google does not publish a fixed timeline for LegitScript-plus-Google certification, so treat any specific day-count you hear from an agency as unverified rather than confirmed policy. What is published: ordinary ad review is typically complete within 24 hours, though Google, Meta and TikTok all note review can run longer, and ads can be re-reviewed after they go live regardless of how long the account has run clean.

Certification covers two separate things, not one. The LegitScript or NABP layer verifies the underlying business — licensure, product legitimacy, prescribing practices — while Google's own advertiser certification is what actually authorizes keyword-targeting of restricted terms once the first layer is in place. Google is also expanding its advertiser verification program toward eventually requiring all advertisers to verify, and submitting false information during that process counts as a circumventing-systems violation in its own right.

What earns a health domain a permanent suspension?

Circumventing systems earns the permanent kind, and Google says so in one sentence: accounts caught manipulating text, images, domains or subdomains to bypass detection are "suspended upon detection and without prior warning, and you will not be allowed to advertise with Google Ads again." That is a harder line than ordinary policy violations, which route through disapproval and appeal rather than permanent exile.

Coordinated deceptive practices and unacceptable business practices sit in the same egregious-violation tier as circumventing systems, meaning immediate suspension without the warning period that ordinary Misrepresentation subsections like unreliable claims or clickbait ads get. Destination mismatch — where the display URL's domain doesn't match the final landing page — is a common trigger inside cloaked supplement funnels, and Google's AdsBot crawler checks that functionally, not on the honor system.

For accounts still inside the ordinary appeal path, the mechanics are procedural: file through Policy Manager, expect roughly 24 hours for initial review, and know the cap sits at 3 appeals per ad. Starting July 21, 2026, Google stopped accepting direct appeals for decisions older than 6 months, so a disapproval left unaddressed for half a year becomes effectively permanent by default. Working through what actually reverses a Google Ads misrepresentation suspension beats guessing at which lever to pull.

Quick decision checklist

Use this page as a decision aid, not a generic blog post. The practical question is whether the reader needs faster evidence about what is already working in VSL-driven direct response, especially across nutra, supplements, GLP-1, weight loss, blood sugar, and adjacent high-intent health markets.

Daily Intel Service is most relevant when the next decision depends on active market examples: which hook to test, which claim style is risky, which funnel structure is common, which language market is moving, and whether a competitor's creative is likely early, scaling, or already saturated.

• Start with the TL;DR if you need the direct answer.
• Use the table to compare trade-offs quickly.
• Use the FAQ for answer-engine-ready summaries.
• Use the CTA when the decision requires live VSL and ad examples instead of theory.

Daily Intel's coverage advantage

Daily Intel Service is positioned around category-leading variety and actionability: one of the broadest direct-response catalogs of VSLs and ad creatives across blackhat, greyhat, and whitehat advertising patterns, with enough context to understand what the advertiser is doing beyond the visible creative. The practical difference is that members are not just seeing a screenshot; they are seeing the VSL, the ad, the funnel path, the transcript, the UTM context, and the research notes that turn the asset into a decision.

This matters because direct-response affiliates do not operate in one clean category. A weight-loss campaign may use a whitehat compliance ad, a greyhat pre-lander, a more aggressive VSL, and a checkout path designed around upsells and recovery. A useful intelligence platform needs to capture that spectrum instead of pretending every winning campaign looks like a public brand ad.

Blackhat, whitehat, and multilingual signal coverage

Daily Intel tracks patterns across both blackhat-style and whitehat-style campaigns so operators can understand the market without blindly copying risk. Whitehat examples help with durability and compliance review; blackhat and greyhat examples reveal pressure points, hooks, mechanisms, and funnel structures that may be driving spend but require careful adaptation before use.

The catalog is also built for global operators, with VSL and ad references spanning 14+ languages and different local idioms. That is a key advantage for Brazilian, LATAM, European, MENA, Indian, and non-native English affiliates who need to see how the same market desire is translated across cultures instead of only studying US English ads.

How to use the intelligence responsibly

The goal is modeling, not copying. Use Daily Intel to understand structure: hook, mechanism, proof, claim intensity, funnel depth, offer economics, and saturation stage. Then build original creative, review claims, and adapt the angle to the traffic source, country, language, and compliance requirements of the campaign.

A strong workflow compares multiple examples before acting. If the same mechanism appears across several languages, several advertisers, and several funnel variants, it may be a durable market signal. If the example appears only once or depends on an aggressive claim, treat it as a research clue rather than a campaign template.

• Model structure, not protected creative assets.
• Separate whitehat durability from blackhat persuasion pressure.
• Compare US English examples against LATAM, European, and other language variants.
• Use transcripts and funnel notes to build original briefs.
• Keep compliance review separate from market research.

Methodology and source context

Daily Intel pages are written from a research workflow that reviews active VSLs, Meta ad creatives, transcripts, UTMs, funnel paths, checkout steps, upsells, recovery sequences, and compliance-sensitive claim patterns. The goal is to explain observable market behavior, not to provide legal, medical, or platform policy advice.

When the topic touches health claims, platform policy, or GLP-1 market research, validate the observable campaign signals against primary references such as FDA human drug compounding, FTC health claims guidance, and Meta advertising standards. Daily Intel adds the proprietary direct-response layer by mapping how those rules show up in active VSLs, Meta creatives, funnels, transcripts, UTMs, and checkout paths.

For deeper evaluation, continue through Nutra niche intelligence directory, Nutraceutical Contract Manufacturer India, Private Label Supplements No Minimum Order Uk, GLP-1 Affiliate Marketing Intelligence, What is a VSL?, and UTM parameter decoding guide. These related Daily Intel pages connect this topic to the relevant methodology, pricing, trust context, comparison path, or niche workflow.